PATENT CLAIM ANALYSIS

Application Number: 15950707
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "170000"]

Abstract:
Provided are methods and compositions, for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib; a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.

Claim (Index 33):
The composition according to  claim 31  or claim  3232  wherein the composition comprises about 100 to about 350 mg of the niraparib, about 100 to about 1500 mg of the abiraterone acetate, and about 2 to about 15 mg of the prednisone.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 91.0
- Lexical Diversity: 1.75758
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13034340', '14607732', '15551708', '15852551', '15337274']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7214395814364921
- 35 USC 102 Novelty (BERT): 0.5293935548026402
- Combined Prediction Score: 0.702234978773107
- Mean Citation Score: 276.71241000000003
- Max Citation Score: 306.766
- Similarity Product: 211.247351700306

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test